Table 1 |
||||||||||||||
|
IC50 Table |
||||||||||||||
|
MCF-7 |
MCF-7/DoxoR |
Loewe interaction index |
SK-BR-3 |
SK-BR-3/NOdoxo |
MDA-MB-231 |
MDA-MB-231/DoxoR |
||||||||
|
IC50 (μM) |
R sq |
IC50 (μM) |
R sq |
MCF_7 |
MCF-7/DoxoR |
IC50 (μM) |
R sq |
IC50 (μM) |
R sq |
IC50 (μM) |
R sq |
IC50 (μM) |
R sq |
|
|
|
||||||||||||||
|
Doxorubicin |
0,04 |
0,96 |
10 |
0,96 |
antagonist |
n.c. |
10 |
0,95 |
50 |
0,97 |
5 |
0,95 |
75 |
0,94 |
|
Rottlerin |
0,005 |
0,96 |
n.c. |
n.c. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
n.d. |
||
|
|
||||||||||||||
|
IC50 Table. IC50s of 24 h drug-treated MCF-7 and MCF-7/DoxoR cells. Data obtained were in luminescence units and analyzed with Graphpad Prism software, n.c. not convergent, n.d. not done. |
||||||||||||||
|
Latorre et al. Molecular Cancer 2012 11:13 doi:10.1186/1476-4598-11-13 |
||||||||||||||
